Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of...

Related Keywords

Japan ,United Kingdom ,San Diego ,California ,United States ,Ankara ,Turkey ,France ,American ,Christophe Le Tourneau ,Jean Pierre Delord ,Joseph Jasper ,Christian Ottensmeier ,Frazer Hall Sylvie Berrebi ,Transgene Euronext ,Yujie Zhao ,Lucie Larguier ,Alessandro Riva ,Masamitsu Kitase ,Institut Curie ,Oliver Lantz ,Ai Drug Development Division ,Clatterbridge Cancer Centre ,University Of Liverpool ,Twitter ,American Association For Cancer Research ,Nec Ai Drug Development Business ,Head Of The Department Drug Development ,Linkedin ,Life Sciences Division ,Euronext Paris ,American Association ,Cancer Research ,Annual Meeting ,Modified Vaccinia Ankara ,Consultant Medical Oncologist ,Drug Development ,Artificial Intelligence ,Development Business ,Risk Factors ,Universal Registration Document ,